Swiss biotech Roivant Sciences’s business model could be regarded, across the biotech world, as slightly unorthodox. The firm, which focuses on developing drugs through subsidiary companies it develops called ‘vants’, has now built over 20 portfolio companies that have completed nine Phase III trials, eight of which have been successful.
Roivant Is Striving Towards New Standards Of Care
Firm Has A Busy 2023 Ahead With Several Promising Data Readouts Expected
With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.
